Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Last trade$7.24
Day change-$0.39 (-5.11%)
Day range$7.08 – $7.76
Volume103,004
Market cap$425M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for OCS.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for OCS.
Recent news
Company coverage with links to the original publishers.
Oculis Holding AG (OCS) has a mean analyst price target of $36.90, suggesting 384.9% upside potential from its current $7.61 price. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions over the past 30 days. However, the article cautions that analyst price targets can be misleading and should not be the sole basis for investment decisions, as they often reflect business incentives rather than realistic valuations.
Oculis announced an R&D Day on December 8, 2026, to showcase its late-stage pipeline including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. Licaminlimab's PREDICT-1 registrational trial has completed patient randomization with topline results expected around year-end, while Privosegtor is advancing through the PIONEER program with anticipated IND clearance this quarter for acute MS relapse indication.
Oculis Holding AG announced an R&D Day scheduled for December 8, 2026, to present clinical and strategic milestones for its late-stage development drugs. Licaminlimab, eye drops containing a TNF-α inhibitor for dry eye disease, has completed patient randomization in the PREDICT-1 registrational trial with topline results expected around year-end. Privosegtor, a neuroprotective therapy for optic neuritis and other neuro-axonal diseases, is advancing through the PIONEER program with an anticipated IND application approval this quarter. The company will feature leading international ophthalmology and neurology experts at the virtual and in-person event.
Oculis Holding AG (OCS) reported a quarterly loss of $0.37 per share, beating consensus estimates of $0.49 loss by 24.49%, but revenues of $0.01 million significantly missed expectations by 96.93%. The stock has declined 61.4% year-to-date, underperforming the S&P 500's 10.2% gain. Despite the miss, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.
Oculis Holding AG is expected to report a quarterly loss of $0.49 per share with revenues of $0.29 million for Q3 2026. However, the company has a positive Earnings ESP of +3.09% combined with a Zacks Rank #2 (Buy), suggesting it will likely beat consensus EPS estimates. The company previously delivered a significant earnings surprise of +58.33% in the last quarter.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.